Infliximab for psoriasis and psoriatic arthritis - PubMed (original) (raw)
. 2002 Nov-Dec;20(6 Suppl 28):S122-5.
Affiliations
- PMID: 12463461
Infliximab for psoriasis and psoriatic arthritis
C Antoni et al. Clin Exp Rheumatol. 2002 Nov-Dec.
Abstract
Tumor Necrosis Factor alpha (TNF) as proinflammatory cytokine plays in the pathogenesis of many diseases an important role. In psoriasis and in psoriatic arthritis TNF is up-regulated in the skin lesion and in the synovitis. Recent trials showed that the blockade of TNF with the chimeric antibody infliximab is able to improve both, the skin lesions and the synovitis of the joints. In psoriasis in 82% of patients treated with infliximab achieved an over 75% response in the PASI index. In Psoriatic arthritis the skin improvement was correlating with the reduction of synovitis and in a small MRI controlled study all patients achieved an ACR 20 response within 10 weeks. Patients with psoriatic arthritis, who have been included in spondylarthopathy trials showed similar improvement rates. In all trials unexpected safety problems have not been reported, but the trials have been small in population and short in duration. Infliximab was used between 5 and 10 mg/kg at week 0, 2, 6 and every 8 week. It some trials the retreatment periods varied. In contrast to the treatment of rheumatoid arthritis with infliximab methotrexate was not always used as comedication. In some cases infliximab has been used in combination with other DMARDs but no trial did evaluate the combination treatment vs. the monotherapy.
Similar articles
- Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J. Antoni CE, et al. Arthritis Rheum. 2005 Apr;52(4):1227-36. doi: 10.1002/art.20967. Arthritis Rheum. 2005. PMID: 15818699 Clinical Trial. - TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
Tobin AM, Kirby B. Tobin AM, et al. BioDrugs. 2005;19(1):47-57. doi: 10.2165/00063030-200519010-00006. BioDrugs. 2005. PMID: 15691217 Review. - Infliximab monotherapy for refractory psoriasis: preliminary results.
Cassano N, Loconsole F, Amoruso A, Coviello C, Filieri M, Filotico R, Del Vecchio S, Vena GA. Cassano N, et al. Int J Immunopathol Pharmacol. 2004 Sep-Dec;17(3):373-80. doi: 10.1177/039463200401700317. Int J Immunopathol Pharmacol. 2004. PMID: 15461871 Clinical Trial. - Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab.
Cauza E, Spak M, Cauza K, Hanusch-Enserer U, Dunky A, Wagner E. Cauza E, et al. Rheumatol Int. 2002 Nov;22(6):227-32. doi: 10.1007/s00296-002-0246-3. Epub 2002 Sep 4. Rheumatol Int. 2002. PMID: 12426660 Clinical Trial. - Infliximab in psoriasis and psoriatic arthritis.
Papoutsaki M, Osório F, Morais P, Torres T, Magina S, Chimenti S, Costanzo A. Papoutsaki M, et al. BioDrugs. 2013 Jan;27 Suppl 1:13-23. doi: 10.1007/BF03325638. BioDrugs. 2013. PMID: 23990278 Review.
Cited by
- A descriptive analysis of real-world treatment patterns of innovator (Remicade®) and biosimilar infliximab in an infliximab-naïve Turkish population.
Yazici Y, Xie L, Ogbomo A, Ellis LA, Goyal K, Teeple A, Mutlu EA, Simsek I. Yazici Y, et al. Biologics. 2018 Oct 2;12:97-106. doi: 10.2147/BTT.S172241. eCollection 2018. Biologics. 2018. PMID: 30323555 Free PMC article. - The critical role of macrophages in the pathogenesis of hidradenitis suppurativa.
Shah A, Alhusayen R, Amini-Nik S. Shah A, et al. Inflamm Res. 2017 Nov;66(11):931-945. doi: 10.1007/s00011-017-1074-y. Epub 2017 Jun 27. Inflamm Res. 2017. PMID: 28656364 Review. - A Case of Severe Panuveitis Associated with Psoriasis Vulgaris Successfully Treated with Infliximab.
Sakurai Y, Namba K, Mizuuchi K, Nomura T, Ishida S. Sakurai Y, et al. Case Rep Ophthalmol. 2016 Apr 2;7(1):191-4. doi: 10.1159/000445285. eCollection 2016 Jan-Apr. Case Rep Ophthalmol. 2016. PMID: 27239187 Free PMC article. - Heel pain due to psoriatic arthritis in a 50 year old recreational male athlete: case report.
Yedon DF, Howitt S. Yedon DF, et al. J Can Chiropr Assoc. 2011 Dec;55(4):288-93. J Can Chiropr Assoc. 2011. PMID: 22131565 Free PMC article. - Patterns of biologic agent use in older males with inflammatory diseases: an institution-focused, observational post-marketing study.
Tran S, Hooker RS, Cipher DJ, Reimold A. Tran S, et al. Drugs Aging. 2009;26(7):607-15. doi: 10.2165/11316350-000000000-00000. Drugs Aging. 2009. PMID: 19655827
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical